Skip to main content
Premium Trial:

Request an Annual Quote

Biosift Acquires Entigen s Technology Assets

NEW YORK, March 24 - Cambridge, Mass.-based bioinformatics firm Biosift said today that it has acquired Entigen's intellectual property and technology assets, which have been in a state of suspension since Entigen closed its offices last March.

 

Biosift purchased rights to Entigen's BioNavigator genomics portal and Adaapt data integration technology. These tools will be integrated with Biosift's Radia sequence analysis package and Scintilla genome browser.

 

Entigen was formed in December 2000 by the merger of bioinformatics ASP eBioinformatics and integration technology provider Empatheon. It maintained offices in Sydney, Australia, and Sunnyvale, Calif., before shutting its doors a year ago following an unsuccessful attempt to raise additional funding.

 

Bala Manian, chairman of the board at Entigen, told GenomeWeb.com's sister publication BioInform last April that the company's tools and assets were "being held in abeyance" while he sought a buyer for the technology.

 

"The company's not closed down," he said at the time, noting that he hoped to sell the technology in one piece rather than split it between several buyers.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.